Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

936
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
936
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

1.1K
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.1K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

487
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
487
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

822
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
822
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

3.2K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.2K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

757
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
757

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

cAMP production secondary to A<sub>2A</sub> adenosine receptor activation as a biomarker of ischemia-reperfusion process: A comparative pilot study between CABG and PCI.

International journal of cardiology·2026
Same author

Artificial intelligence adoption in French cardiovascular care: a multiprofessional survey of barriers and facilitators.

European heart journal. Digital health·2026
Same author

Catheter-directed versus standard therapy in intermediate-high-risk pulmonary embolism: A retrospective cohort study.

Archives of cardiovascular diseases·2025
Same author

Pharmacologic Profile of A<sub>2A</sub> Adenosine Receptors: Identifying Patients with Intermittent Claudication and Associated Myocardial Ischemia.

CJC open·2025
Same author

Non-bacterial thrombotic endocarditis in cancer.

European heart journal·2025
Same author

Distinct Inflammatory Responses of hiPSC-Derived Endothelial Cells and Cardiomyocytes to Cytokines Involved in Immune Checkpoint Inhibitor-Associated Myocarditis.

Cells·2025

Related Experiment Video

Updated: Jan 26, 2026

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

3.4K

Dynamic iron status after acute heart failure.

Laura Sportouch1, Jennifer Cautela1, Noémie Resseguier2

  • 1Heart Failure and Valvular Heart Disease Unit, Mediterranean University Cardio-Oncology (MEDI-CO) Centre, Department of Cardiology, Aix-Marseille University, hôpital Nord, AP-HM, chemin des Bourrely, 13015 Marseille, France; Inserm 1263, INRA, centre de recherche cardiovasculaire et nutrition (C2VN), Aix-Marseille University, 13385 Marseille, France.

Archives of Cardiovascular Diseases
|April 23, 2019
PubMed
Summary

Iron deficiency (ID) in acute heart failure (HF) patients is common and dynamic. Iron status fluctuates significantly between hospital admission and discharge, highlighting the need for careful monitoring in HF management.

Keywords:
Acute heart failureCarence en ferCo-morbidityComorbiditéInsuffisance cardiaque aiguëIron deficiency

More Related Videos

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
04:05

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

2.8K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

557

Related Experiment Videos

Last Updated: Jan 26, 2026

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

3.4K
Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
04:05

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

2.8K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

557

Area of Science:

  • Cardiology
  • Hematology
  • Internal Medicine

Background:

  • Iron deficiency (ID) is prevalent in heart failure (HF) patients, correlating with poorer clinical outcomes.
  • Current guidelines recommend screening for ID in HF, but optimal assessment timing remains unclear.

Purpose of the Study:

  • To investigate the dynamic changes in iron status during short-term follow-up in patients hospitalized for acute heart failure.
  • To analyze the prevalence and variations of iron deficiency at different time points in acute HF patients.

Main Methods:

  • Assessed iron status (serum ferritin, transferrin saturation) in 110 acute HF patients at admission, discharge, and 1 month post-discharge.
  • Defined iron deficiency based on established clinical guidelines.
  • Correlated changes in iron status with inflammatory markers like C-reactive protein and patient characteristics.

Main Results:

  • Iron deficiency prevalence was high at admission (75%), decreased at discharge (61%), and returned to admission levels by 1 month (70%).
  • Significant changes in iron status occurred between admission and discharge (P=0.0018).
  • Iron status varied in 25% of patients despite similar overall prevalence at admission and 1 month; advanced age, anemia, and low ferritin predicted persistent ID.

Conclusions:

  • Iron status is highly dynamic in patients hospitalized with acute heart failure.
  • While iron deficiency prevalence may appear similar at admission and one month post-discharge, individual iron status can fluctuate significantly during this period.
  • These findings underscore the importance of monitoring iron status throughout the management of acute heart failure.